Department of Clinical Oncology, Kobe City Medical Center General Hospital, 2-1-1, Minatojima Minamimachi, Chuo-Ku, Kobe, Hyogo, 6500047, Japan.
Cancer Treatment Center, Kansai Medical University, 2-3-1, Hirakatashinmachi, Hirakata, Osaka, 573-1191, Japan.
Sci Rep. 2023 Feb 10;13(1):2433. doi: 10.1038/s41598-023-29706-6.
Regorafenib is a standard salvage line therapy used for advanced colorectal cancer (CRC). Recently, trifluridine/tipiracil (TFTD) plus bevacizumab also showed promising efficacy as a salvage line therapy for advanced CRC. However, the efficacy and safety of regorafenib for patients with advanced CRC who have previously received TFTD plus bevacizumab is unclear. We retrospectively collected clinicopathologic data from patients with advanced CRC who received regorafenib after TFTD plus bevacizumab in multiple institutions between April 2017 and June 2020.Thirty-four advanced CRC patients who received regorafenib were analyzed. The median age was 66.5 (range 43-81 years), 11 patients were male, and all had an ECOG performance status(PS) of 0 or 1. Twenty-two patients had left-sided tumors, 18 patients had RAS mutants, and 1 patient had a BRAF V600E mutation. The response rate was 0%, and the disease control rate was 31%. The median progression-free survival was 70 days (95% CI: 56-91), and the overall survival was 233 days (95% CI: 188-324). Treatment was discontinued in 32 patients, and 28 (82%) discontinued treatment due to progressive disease. The major grade 3 and4 toxicities were proteinurea (29%), hypertension (26%), hand-foot syndrome(15%), and platelet decrease (6%). Regorafenib after TFTD plus bevacizumab showed efficacy similar to that of the previous study, and no new adverse events were observed.
瑞戈非尼是一种标准的挽救线治疗药物，用于治疗晚期结直肠癌（CRC）。最近，三氟尿苷/替匹嘧啶（TFTD）联合贝伐珠单抗也显示出作为晚期 CRC 挽救线治疗的有前途的疗效。然而，瑞戈非尼在先前接受 TFTD 联合贝伐珠单抗治疗的晚期 CRC 患者中的疗效和安全性尚不清楚。我们回顾性地收集了 2017 年 4 月至 2020 年 6 月期间多个机构接受瑞戈非尼治疗的先前接受 TFTD 联合贝伐珠单抗治疗的晚期 CRC 患者的临床病理数据。分析了 34 例接受瑞戈非尼治疗的晚期 CRC 患者。中位年龄为 66.5 岁（范围 43-81 岁），11 例为男性，所有患者的 ECOG 表现状态（PS）均为 0 或 1。22 例为左侧肿瘤，18 例为 RAS 突变，1 例为 BRAF V600E 突变。客观缓解率为 0%，疾病控制率为 31%。中位无进展生存期为 70 天（95%CI：56-91），总生存期为 233 天（95%CI：188-324）。32 例患者停止治疗，28 例（82%）因疾病进展而停止治疗。主要的 3 级和 4 级毒性为蛋白尿（29%）、高血压（26%）、手足综合征（15%）和血小板减少（6%）。瑞戈非尼在 TFTD 联合贝伐珠单抗之后显示出与先前研究相似的疗效，并且没有观察到新的不良反应。
